AmirTFathiMD

PubMed

• Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
  Courtney D D DiNardo, Gail J Roboz, Justin M Watts, Yazan F Madanat, Gabrielle T Prince, Praneeth Baratam, Stéphane de Botton, Anthony S Stein, James M Foran, Martha L...> ;Blood Advances. 2024 Apr 19
• Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
  Alberto Risueño, Wendy L See, Iryna Bluemmert, Stéphane de Botton, Andre C Schuh, Pau Montesinos, Paresh Vyas, Anita Gandhi, Maroof Hasan, Courtney D DiNardo, Amir T F...> ;Leukemia Research. 2024 Mar 27
• Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.
  Pau Montesinos, Stéphane de Botton, Yue Zhu, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Amir T Fathi, Eytan M Stein, Amer M Zeidan, Thomas Prebet, Courtney D DiNardo> ;Blood Advances. 2024 Mar 20
• A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
  Mark J Levis, Alexander E Perl, Gary J Schiller, Amir T Fathi, Gail J Roboz, Eunice S Wang, Jessica K Altman, Trivikram Rajkhowa, Makoto Ando, Takeaki Suzuki, Ruth Ann...> ;Blood Advances. 2024 Mar 19
• Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
  Colak, G., Fusco, A., Mangan, J., Stein, E., Fathi, A., Harb, W.> ;Leukemia & Lymphoma. 2024 Apr 1
• Traditional Medicare or Medicare Advantage? The Leukemia and Cancer Perspective.
  Rajkumar, V., Kantarjian, H., Zeidan, A., Fathi, A., Stein, E., Tefferi, A.> ;Mayo Clinic Proceedings. 2024 Jan 1
• Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment.
  Amir T Fathi> ;The Lancet. Haematology. 2023 Nov 1
• Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study.
  Arnaud Lesegretain, Andrew Brunner, Aziz Benzohra, Amir T Fathi> ;Leukemia & Lymphoma. 2023 Dec 1
• 3 citations
  Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
  Shallis, R., Daver, N., Altman, J., Komrokji, R., Pollyea, D., Badar, T., Bewersdorf, J., Bhatt, V., de Botton, S., de la Fuente Burguera, A., Carraway, H., Desai, P.,...> ;The Lancet. Haematology. 2023 Sep 1
• Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
  Courtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, Richard M Stone, Jessica K Altman, Amir T Fathi, Tharin Limsakun, Min Liang, Sung Choe, Mohammad Hossain, Adr...> ;American Journal of Hematology. 2023 Sep 1
• 1 citations
  Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
  Manish R Patel, William Donnellan, Michael Byrne, Adam S Asch, Amer M Zeidan, Maria R Baer, Amir T Fathi, Andrew T Kuykendall, Fred Zheng, Chris Walker, Lulu Cheng, Ci...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
• 15 citations
  Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
  Daniel A Pollyea, Jessica K Altman, Rita Assi, Dale Bixby, Amir T Fathi, James M Foran, Ivana Gojo, Aric C Hall, Brian A Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori...> ;Journal of the National Comprehensive Cancer Network. 2023 May 1
• 4 citations
  Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
  Amir T Fathi, Haesook T Kim, Robert J Soiffer, Mark J Levis, Shuli Li, Annette S Kim, Zachariah DeFilipp, Areej El-Jawahri, Steve L McAfee, Andrew M Brunner, Philip C ...> ;Clinical Cancer Research. 2023 Jun 1
• 4 citations
  Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial.
  El-Jawahri, A., Luskin, M., Greer, J., Traeger, L., Lavoie, M., Vaughn, D., Andrews, S., Yang, D., Boateng, K., Newcomb, R., Ufere, N., Fathi, A., Hobbs, G., Brunner, ...> ;Cancer. 2023 Apr 1
• 17 citations
  Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
  Guillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, Jessica K Altman, Amir T Fathi, Olatoyosi Odenike, Gail J Roboz, Kendra Sweet, Crystal Miller, Anders Wennborg...> ;The Lancet. Haematology. 2023 Apr 1
• 12 citations
  North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
  Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R Wilson, Marina Konopleva, Arthur E Frankel, Vikas Gupta, Ruben Mesa, Matth...> ;Blood. 2023 Feb 9
• 1 citations
  Comparison of demographics, disease characteristics, and outcomes between Black and White patients with myelodysplastic syndromes: A population-based study.
  Arnaud Lesegretain, Andrew Brunner, Andrew J King, Abderrahmane Laadem, Geoffrey Fell, Amir T Fathi> ;Leukemia Research. 2023 Feb 1
• 20 citations
  Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
  Fathi, A., Kim, H., Soiffer, R., Levis, M., Li, S., Kim, A., Mims, A., DeFilipp, Z., El-Jawahri, A., McAfee, S., Brunner, A., Narayan, R., Knight, L., Kelley, D., Bott...> ;Blood Advances. 2022 Nov 22
• 3 citations
  Relationship Between Longitudinal Coping Strategies and Outcomes in Patients With Acute Myeloid Leukemia.
  Hermioni L Amonoo, Elizabeth Daskalakis, Emma C Deary, Monica H Bodd, Matthew J Reynolds, Ashley M Nelson, Richard Newcomb, Tejaswini M Dhawale, Daniel Yang, Selina M ...> ;Journal of the National Comprehensive Cancer Network. 2022 Oct 1
• A New Dancing Partner for Venetoclax: Gilteritinib.
  Amir T Fathi> ;Journal of Clinical Oncology. 2022 Dec 10
• 7 citations
  Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.
  Vladimir Ivanov, Su-Peng Yeh, Jiri Mayer, Lalit Saini, Ali Unal, Michael Boyiadzis, David M Hoffman, Kingston Kang, Sadiya N Addo, Wellington L Mendes, Amir T Fathi> ;Future Oncology. 2022 Aug 1
• 8 citations
  Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.
  Megan J Fitzpatrick, Leonardo Boiocchi, Amir T Fathi, Andrew M Brunner, Robert P Hasserjian, Valentina Nardi> ;Histopathology. 2022 Oct 1
• 4 citations
  Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.
  Dora Dias-Santagata, Rebecca S Heist, Adam Z Bard, Annacarolina F L da Silva, Ibiayi Dagogo-Jack, Valentina Nardi, Lauren L Ritterhouse, Laura M Spring, Nicholas Jesso...> ;The Oncologist. 2022 Nov 3
• 2 citations
  Patients with myeloproliferative neoplasms and COVID-19 have increased rates of arterial thrombosis.
  Orly Leiva, Umberto Campia, Julia Snyder, Briana M Barns, Samantha Rizzo, Candrika D Khairani, Andrew Brunner, Hanny Al-Samkari, Rebecca Karp Leaf, Rachel Rosovsky, Ka...> ;Research and Practice in Thrombosis and Haemostasis. 2022 Jul 1
• 26 citations
  Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
  Stéphane de Botton, Pau Montesinos, Andre C Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A Larson, Jaime ...> ;Blood. 2023 Jan 12
• Join now to see all

Journal Articles

• Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia  
  Areej El-Jawahri, Thomas W Leblanc, Selina M Luger, Bhavana Bhatnagar, Alison R Walker, Amir T Fathi, Andrew M Brunner, Gabriela S Hobbs, Jennifer S Temel, JAMA Oncology
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML  
  Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

• High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...
  Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia
  Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of th...
  Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
  Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
  Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myelo...
  Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• AML: Expert Guidance on Current Standards and New Directions in Patient Care 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Hematologic Malignancies and Hematology Update 2013 
  Harvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 4/5/2013
• Join now to see all